NTLA Downgrade to Underperform. Cash Concerns & TTR Value May Further Compress

Research evidence excerpt

NTLA Downgrade to Underperform. Cash Concerns & TTR Value May Further Compress

Biotechnology - Immunology

Genetic Medicines - Market Weight

INTELLIA THERAPEUTICS, INC. (NTLA) July 15, 2026

NTLA Downgrade to Underperform. Cash Concerns & TTR Rating:

Value May Further Compress Underperform

Prior: Peer Perform

Price:

The Wolfe Byte $13.30

Turning pessimistic on NTLA's narrative. We foresee cash issue & TTR value may Price Target:

$9come under further pressure. However, we do not view this as a great short idea Prior: NA

given M&A risk. Downgrade to Underperform and revise PT to $9/share. % Upside:

(32.3)%

View NTLA Model

Our primary concern is cash constraint. Both Alnylam and Astra likely View Comp Table

underestimated the event rate in "placebo" patients given improved health, and

Company InformationIntellia may have also miscalculated which would prolong TTR-CM expenses and

52-Week Range $8 - $28

strain cash. Recall, Intellia upsized MAGNITUDE enrollment (from 765 to ~1,200 Market Cap. (M) $1,858

patients) to ensure a more robust dataset, 'particularly in the stabilizer stratum' (link). Shares Out. (MM) 139.7

However, management appears to be happy with 70-75% and even high-70%s Avg. Value Traded (MM) $97.90 SI% of Float 36.9%

exposure to tafamidis background (whereas Astra's failure is attributed to 81% Dividend Yield 0.0%

tafamidis background). A trial delay may inflate the size of Intellia's next raise & push

Price Performance

cashflows into outer years.

YTD LTM

Intellia must be highly diligent on the path to cashflow generation. Unlike chronic NTLA 48% 11% SPX 10% 20%

therapies, the one-time gene therapy makes a reliable J-code more important. It may

be tricky to optimize cost discipline as the company will need to field a salesforce but 30